Miyagi, Japan

Masahiro Usui

This inventor holds 1 USPTO granted patent. Top assignees: Nihon University, Nippon Kayaku Kabushiki Kaisha, Osaki City. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masahiro Usui. Retrieved from https://idiyas.com/inventor/masahiro-usui-l3w2fske

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masahiro Usui: Innovator in SGLT2 Inhibitor Sensitivity

Introduction

Masahiro Usui is a notable inventor based in Miyagi, Japan. He has made significant contributions to the field of medical research, particularly in the area of SGLT2 inhibitors. His work focuses on developing methods to determine sensitivity to these inhibitors, which are crucial in managing diabetes.

Latest Patents

Masahiro Usui holds a patent for a "Method for determining sensitivity to SGLT2 inhibitor and sensitivity marker for SGLT2 inhibitor." The objective of this invention is to provide a reliable method for assessing a subject's sensitivity to SGLT2 inhibitors. This method involves measuring a biomarker in a biological sample and using the measured value to determine sensitivity.

Career Highlights

Throughout his career, Usui has worked with reputable institutions, including Nihon University and Osaki City. His experience in these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

Some of his notable coworkers include Tadateru Takayama and Keiko Kudo. Their collaboration has likely enriched the research environment and fostered innovative ideas in their respective fields.

Conclusion

Masahiro Usui's contributions to the understanding of SGLT2 inhibitors highlight his role as an important inventor in medical research. His patented method for determining sensitivity to these inhibitors represents a significant advancement in diabetes management.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…